Список литератур ы
1. Brandt LJ, Locke GR, Olden K, Quigley E, Schoenfeld P, Schuster M, Talley N. An evidence-based approach to the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002;97(Suppl):S1–S26.
2. Drossman DA, Camileri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123:2108-2131.
3. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999;45(Suppl II):II43–II47.
4. Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut 2000;46:78-82.
5. Hungin APS, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003;17: 643-650.
6. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000;133:136-147.
7. Jones J, Boorman J, Cann P, Forbes A, Gomborone J, Heaton K, Hungin P, Kumar D, Libby G, Spiller R, Read N, Silk D, Whorwell P. British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut 2000;47(Suppl II):ii1– ii19.
8. Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001;48: 272-282.
9. Camilleri M. Management of the irritable bowel syndrome. Gas-troenterology 2001;120:652–668.
10. Talley NJ. Pharmacologic therapy for the irritable bowel syndrome. Am J Gastroenterol 2003;98:750–758.
11. Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994;8:499–510. 12. Quigley EMM. Current concepts of the irritable bowel syndrome. Scand J Gastroenterol 2003;38(Suppl 237):1–8.
13. Mayer EA, Collins SM. Evolving pathophysiological models of functional gastrointestinal disorders. Gastroenterology 2002; 122:2032–2048.
14. McKendrick MW, Read MW. Irritable bowel syndrome—post-salmonella infection. J Infect 1994;29:1–3.
15. Neal KR, Hebdon J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome. BMJ 1997;314:779–782.
16. Gwee K-A, Leong Y-L, Graham C, McKendrick MW, Collins SM, Walters SJ, Underwood JE, Read NW. The role of psychological and biological factors in post-infective gut dysfunction. Gut 1999; 44:400–406.
17. Garcia Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ 1999;318:565–566.
18. Spiller RC. Estimating the importance of infection in IBS. Am J Gastroenterol 2003;98:238–241.
19. Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000;47:804–811.
20. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003;125:1651–1659.
21. Cumberland P, Sethi D, Roderick PJ, Wheeler JG, Cowden JM, Roberts JA, Rodrigues LC, Hudson MJ, Tompkins DS; IID Study Executive. The infectious intestinal disease study of England: a prospective evaluation of symptoms and health care use after an acute episode. Epidemiol Infect 2003;130:453–460.
22. Collins SM. A case for an immunological basis for irritable bowel syndrome. Gastroenterology 2002;122:2078–2080.
23. Chadwick V, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, Wilson I. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002;122:1778–1783.
24. Tornblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002;123:1972– 1979.
25. O'Sullivan M, Clayton N, Breslin NP, Harman I, Bountra C, McLaren A, O'Morain CA. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil 2000;12:449–457.
26. Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003;52:91–93.
27. Gwee K-A, Collins SM, Read NW, Ranjnakova A, Deng Y, Graham JC, McKendrick MW, Moochhala SM. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut 2003;52:523–526.
28. Pimentel M, Chow EJ, Lin HC. Eradication of small bowel bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000;95:3503–3506.
29. Pimentel M, Chow E, Lin H. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003;98:412–419.
30. Tursi A, Brandimarte G, Giorgetti GM. High prevalence of small intestinal bacterial overgrowth in celiac patients with persistence of gastrointestinal symptoms after gluten withdrawal. Am J Gas-troenterol 2003;98:839–843.
31. O'Leary C, Quigley EMM. Small bowel bacterial overgrowth, celiac disease and IBS: what are the associations? Am J Gastroenterol 2003;98:720–722.
32. Shanahan F. Therapeutic manipulation in gut flora. Science 2000;289:1311–1312.
33. Collins SM. The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology 1996;111:1683–1699.
34. Gorbach SL. Probiotics in the third millennium. Dig Liver Dis 2002;
34(Suppl 2):S2–S7.
35. Isolauri E, Kirjavainen PV, Salminen S. Probiotics: a role in the treatment of intestinal infection and inflammation? Gut 2002;50: iii54 –iii59.
36. Von Wright A, Salminen S. Probiotics: established effects and open questions. Eur J Gastroenterol Hepatol 1999;11:1195– 1198.
37. O'Mahony L, Feeney M, O'Halloran S, Murphy L, Kiely B, Fitzgib-bon J, Lee G, O'Sullivan G, Shanahan F, Collins K.. Probiotic impact on microbial flora, inflammation, and tumour development in IL-10 knockout mice. Aliment Pharmacol Ther 2001;15:1219– 1225.
38. McCarthy J, O'Mahony L, O'Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, Fitzgibbon J, O'Sullivan GC, Kiely B, Collins JK, Shanahan F. Double blind, placebo controlled trial of two probi-otic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 2003;52:975–980.
39. Bradley HK, Wyatt GM, Bayliss CE, Hunter JO. Instability in the faecal flora of a patient suffering from food-related irritable bowel syndrome. J Med Microbiol 1987;23:29–32.
40. Balsari A, Ceccarelli A, Dubini F, Fesce E, Poli G. The fecal microbial population in the irritable bowel syndrome. Microbio-logica 1982;5:185–194.
41. King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998;352:1187–1189.
42. Jiang T, Savaiano DA. Modification of colonic fermentation by bifidobacteria and pH in vitro: impact on lactose metabolism, short-chain fatty acid, and lactate production. Dig Dis Sci 1997; 42:2370–2377.
43. Ouwehand AC, Lagstrom H, Suomalainen T, Salminen S. Effect of probiotics on constipation, fecal azoreductase activity and fecal mucin content in the elderly. Ann Nutr Metab 2002;46:159–162.
44. Halpern GM, Prindiville T, Blankenburg M, Hsia T, Gershwin ME. Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. Am J Gastroenterol 1996; 91:1579–1585.
45. Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000;95:1231–1238.
46. O'Sullivan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis 2000;32:302–304.
47. Brigidi P, Vitali B, Swennen E, Bazzocchi G, Matteuzzi D. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol 2001;152:735– 741.
48. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroen-terol Hepatol 2001;13:1143–1147.
49. Sen S, Mullan MM, Parker TJ, Woolner JT, Tarry SA, Hunter JO. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002;47: 2615–2620.
50. Bazzocchi G, Gionchetti P, Almerigi PF, Amadini C, Campieri M. Intestinal microflora and oral bacteriotherapy in irritable bowel syndrome. Dig Liver Dis 2002;34(Suppl 2):s48–s53.
51. Adler SN, Jacob H, Eliakim R. The probiotic agent E-Coli strain ATCC20226 has a healing effect on proximal inflammation of the small bowel (abstr). Gastroenterology 2002;122:A527.
52. Parker P, McNaught CE, Anderson ADG, Mitchell CJ, MacFie J. Synbiotic in irritable bowel syndrome: a double blind prospective randomised controlled trial (abstr). Gut 2003;52:A11.
53. Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thom-forde GM, Zinsmeister AR. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003;17:895–904.
54. Barbara G, Corinaldesi R. Probiotics: could they turn out to be ineffective in irritable bowel syndrome? Dig Liver Dis 2000;32: 294–301.
55. Hamilton-Miller JMT. Probiotics in the management of irritable bowel syndrome: a review of clinical trials. Microb Ecol Health Dis 2001;13:212–216.
56. Thompson WG. Probiotics for irritable bowel syndrome: a light in the darkness? Eur J Gastroenterol Hepatol 2001;13:1135–1136.
57. Madden JA, Hunter JO. A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics. Br J Nutr 2002;88(Suppl 1):S67–S72.
58. Floch MH. Probiotics, irritable bowel syndrome, and inflammatory bowel disease. Curr Treat Options Gastroenterol 2003;6:283– 288. 59. Dunne C, O'Mahony L, Murphy L, Thornton G, Morrissey D, O'Halloran S, Feeney M, Flynn S, Fitzgerald G, Daly C, Kiely B, O'Sullivan GC, Shanahan F, Collins K. In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings. Am J Clin Nutr 2001;73:886S–892S.
60. Dunne C, Murphy L, Flynn S, O'Mahony L, O'Halloran S, Feeney M, Morrissey D, Thornton G, Fitzgerald G, Daly C, Kiely B, Quigley EMM, O"Sullivan GC, Shanahan F, Collins JK. Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie Van Leeuwen-hoek 1999;76:279–292.
61. Collins JK, Dunne C, Murphy L, Morrissey D, O'Mahony L, O'Sullivan E, Fitzgerald G, Kiely B, O'Sullivan GC, Daly C, Marteau P, Shanahan F. A randomised controlled trial of a probiotic Lac-tobacillus strain in healthy adults: assessment of its delivery, transit, and influence on microbial flora and enteric immunity. Microb Ecol Health Dis 2002;14:81–89.
62. Veldhuyzen Van Zanten SJ, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, Zinsmeister AR. Design of trials for functional gastrointestinal disorders. Gut 1999;45(Suppl 2):II68–II77.
63. Heaton KW, O'Donnell LJ. An office guide to whole-gut transit time. Patients' recollection of their stool form. J Clin Gastroen-terol 1994;19:28–30.
64. Drossman DA, Patrick DL, Whitehead WE, Toner BB, Diamant NE, Hu Y, Jia H, Bangdiwala SI. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol 2000;95:999–1007.
65. Boyum A. Separation of leukocytes from blood and bone marrow. Scand J Clin Lab Invest Suppl 1968;97:7. 66. Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003;15:79–86.
67. Muller-Lissner SA, Fumagalli I, Bardhan KD, Pace F, Pecher E, Nault B, Ruegg P. Tegaserod, a 5-HT receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001;15:1655-1666.
68. Kellow J, Lee OY, Chang FY, Thongsawat S, Mazlam MZ, Yuen H, Gwee KA, Bak YT, Jones J, Wagner A. An Asia-Pacific, double blind, placebo-controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003;52:671-676.
69. Perdigon G, Alvarez S, Nader DE, Macias ME, Roux ME, de Ruiz Holgado AP. The oral administration of lactic acid bacteria increases the mucosal immunity in response to enteropathogens. J Food Protection 1990;53:404-440.
70. Rolfe RD. The role of probiotic cultures in the control of gastrointestinal health. J Nutr 2000;130(2S Suppl):396S-402S.
71. Duffy LC, Leavens A, Griffiths E, Dryja D. Perspectives on bifidobacteria as biotherapeutic agents in gastrointestinal health. Dig Dis Sci 1999;44:1499-1505.
72. Marteau P, Seksisk P, Jian R. Probiotics and intestinal health effects: a clinical perspective. Br J Nutr 2002;88(Suppl 1):S51-S57.
73. Fooks LJ, Gibson GR. Probiotics as modulators of the gut flora. Br J Nutr 2002;88(Suppl 1):S39-S49.
74. Cremonini F, Di Caro S, Santarelli L, Gabrielli M, Candelli M, Nista EC, Lupascu A, Gasbarrini G, Gasbarrini A. Probiotics in antibiotic-associated diarrhoea. Dig Liver Dis 2002;34:S78-S80.
75. Byrne F, Murphy LM, Binder S, Collins JK, O'Sullivan GC, Shana-han F, Aranda R. Prevention of wasting and colitis in SCID mice reconstituted with CD4+ and RB high cells by the administration of the probiotic Bifidobacterium longum infantis. (in press)
76. Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, Akira S, Takeda K, Lee J, Takabayashi K, Raz E. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004;126:520-528. 77. Jijon H, Backer J, Diaz H, Yeung H, Thiel D, McKagney C, De Simone C, Madsen K. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 2004;126:1358-1373.
78. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693-702.
79. Greenwood-van Meerveld B, Johnson AC, Kajs T, Charbonnealu D, Poehner R, Chen K-S, Carryl 0. Probiotic bacteria normalize post inflammatory visceral hyperalgesia in rats (abstr). Gastroenterology 2002;122:A476.
80. Lamine F, Cauquil E, Eutamene H, Fioramonti J, Bueno L, Theodorou V. Lactobacillus farciminis treatment reduces sensitivity to rectal distension in rats: involvement of nitric oxide (abstr). Gastroenterology 2003;122:A476.
81. Quigley EMM. The role of gas in IBS. In: Camilleri M, Spiller RC, eds. Irritable bowel syndrome. Diagnosis and treatment. Philadelphia, PA: Saunders, 2002:77-84.
82. Quigley EMM. From comic relief to real understanding; how intestinal gas causes symptoms. Gut 2003;52:1659-1661.
83. Serra J, Azpiroz F, Malagelada JR. Impaired transit and tolerance of gas in the irritable bowel syndrome. Gut 2001;48:14-19.
84. Alender M, Satokari R, Korpela R, Saxelin M, Vilpponen-Salmela T, Mattila-Sandholm T, von Wright A. Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. Appl Environ Microbiol 1999;65:351-354.
85. Zoetendal EG, von Wright A, Vilpponen-Salmela T, Ben-Amor K, Akkermans ADL, de Vos WM. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl Environ Microbiol 2002;68:3410-3407.
86. Uribe A, Alam M, Johansson O, Midtvedt T, Theodorsson E. Microflora modulates endocrine cells in the gastrointestinal mu-cosa of the rat. Gastroenterology 1994;107:1259–1269.